Abstract
Nine novel mono-oxime reactivators bearing xylene linker were synthesized in an effort to improve previously prepared xylene bisoximes and monocarbamoyl-monooximes. The novel compounds were tested in vitro on the model of tabun-, paraoxon-, methylparaoxon- and DFP-inhibited human erythrocyte AChE. Their reactivation ability was compared to pralidoxime, asoxime, obidoxime and two previously prepared xylene linked bisoximes (K107, K108). All compounds showed minimal reactivation of tabun-inhibited AChE at selected concentration scale. This finding was explained by molecular modelling study. Bisoximes obidoxime and K108 resulted as the best reactivators for paraoxon-, methylparaoxon- and DFP-inhibited AChE. The loss of nonoxime moiety lead to the loss of reactivation ability within the novel compounds. Though the novel reactivators did not exceed previously known compounds, they confirmed former SAR findings for xylene-linked AChE reactivators.
Keywords: Acetylcholinesterase, tabun, DFP, pesticide, reactivator, oxime, xylene linker.
Medicinal Chemistry
Title:Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase
Volume: 12 Issue: 4
Author(s): Kamil Musilek, Jan Hambalek, Ondrej Holas, Vlastimil Dohnal and Kamil Kuca
Affiliation:
Keywords: Acetylcholinesterase, tabun, DFP, pesticide, reactivator, oxime, xylene linker.
Abstract: Nine novel mono-oxime reactivators bearing xylene linker were synthesized in an effort to improve previously prepared xylene bisoximes and monocarbamoyl-monooximes. The novel compounds were tested in vitro on the model of tabun-, paraoxon-, methylparaoxon- and DFP-inhibited human erythrocyte AChE. Their reactivation ability was compared to pralidoxime, asoxime, obidoxime and two previously prepared xylene linked bisoximes (K107, K108). All compounds showed minimal reactivation of tabun-inhibited AChE at selected concentration scale. This finding was explained by molecular modelling study. Bisoximes obidoxime and K108 resulted as the best reactivators for paraoxon-, methylparaoxon- and DFP-inhibited AChE. The loss of nonoxime moiety lead to the loss of reactivation ability within the novel compounds. Though the novel reactivators did not exceed previously known compounds, they confirmed former SAR findings for xylene-linked AChE reactivators.
Export Options
About this article
Cite this article as:
Musilek Kamil, Hambalek Jan, Holas Ondrej, Dohnal Vlastimil and Kuca Kamil, Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase, Medicinal Chemistry 2016; 12 (4) . https://dx.doi.org/10.2174/1573406411666151002125640
DOI https://dx.doi.org/10.2174/1573406411666151002125640 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond
Current Pharmaceutical Biotechnology Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Prepontine Chordoma Presenting with MRI Features of an Epidermoid Cyst: Case Presentation and a Mini-Review
Current Medical Imaging Abnormalities of Peptide Metabolism in Alzheimer Disease
Current Neurovascular Research Recent Advances in Psoriasis Therapy: Trends and Future Prospects
Current Drug Targets Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Integrative Functional Assays, Chemical Genomics and High Throughput Screening: Harnessing Signal Transduction Pathways to a Common HTS Readout
Current Pharmaceutical Design Anticholinesterase and Antioxidant Activities of Natural Abietane Diterpenoids with Molecular Docking Studies
Current Alzheimer Research Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies
Current Neuropharmacology A Therapeutic Paradigm to Appraise the Competence of Chitosan Oligosaccharide Lactate Targeting Monoamine Oxidase-A and PGlycoprotein to Contest Depression by Channeling the Blood Brain Barrier
Current Bioinformatics CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry Exercise Addiction- Diagnosis, Bio-Psychological Mechanisms and Treatment Issues
Current Pharmaceutical Design Delayed Treatment with Nicotinamide Inhibits Brain Energy Depletion,Improves Cerebral Microperfusion, Reduces Brain Infarct Volume, but does not Alter Neurobehavioral Outcome Following Permanent Focal Cerebral Ischemia in Sprague Dawley Rats
Current Neurovascular Research Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry From Ancient Chinese Medicine to a Novel Approach to Treat Cocaine Addiction
CNS & Neurological Disorders - Drug Targets Recent Advances in Selective μ-Opioid Ligands as Evaluated in Animal Models
Central Nervous System Agents in Medicinal Chemistry Recent Patents on Transglutaminase Production and Applications: A Brief Review
Recent Patents on Biotechnology Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Evaluation of Neurobehavioral and Biochemical Parameters of Poly- Herbal Formulation on MPTP-Intoxicated Mice for the Treatment of PD
Current Bioactive Compounds Erratum
Current Alzheimer Research